Evidence map›Paper›PMID 25462575›Full record

ArticlePhotodiagnosis and photodynamic therapy2015

Low-level light therapy potentiates NPe6-mediated photodynamic therapy in a human osteosarcoma cell line via increased ATP.

Shang-Ru Tsai, Rui Yin, Ying-Ying Huang, Bor-Ching Sheu, Si-Chen Lee, Michael R Hamblin

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Photodiagnosis and photodynamic therapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 3 pooled it
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 3 syntheses or guidelines pooled it, 54 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
  5. Article
  6. Review
  7. Article
  8. Light modulatesAging · 2023
    Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Retrospective evaluation of the safety of low-level laser therapy/photobiomodulation in patients with head/neck cancer.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2020
    Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 3 countries.

Shang-Ru TsaiWellman Center for Photomedicine, Massachusetts General Hospital, Boston, MA, USA; Department of Dermatology, Harvard Medical School, Boston, MA, USA; Graduate Institute of Biomedical Electronics and Bioinformatics, National Taiwan University, Taipei, Taiwan.
Rui YinWellman Center for Photomedicine, Massachusetts General Hospital, Boston, MA, USA; Department of Dermatology, Harvard Medical School, Boston, MA, USA; Department of Dermatology, Southwest Hospital, Third Military Medical University, Chongqing, China.
Ying-Ying HuangWellman Center for Photomedicine, Massachusetts General Hospital, Boston, MA, USA; Department of Dermatology, Harvard Medical School, Boston, MA, USA.
Bor-Ching SheuCollege of Medicine, National Taiwan University, Taipei, Taiwan.
Si-Chen LeeGraduate Institute of Biomedical Electronics and Bioinformatics, National Taiwan University, Taipei, Taiwan; Department of Electrical Engineering, National Taiwan University, Taipei, Taiwan.
Michael R HamblinWellman Center for Photomedicine, Massachusetts General Hospital, Boston, MA, USA; Department of Dermatology, Harvard Medical School, Boston, MA, USA; Harvard-MIT Division of Health Sciences and Technology, Cambridge, MA, USA. Electronic address: Hamblin@helix.mgh.harvard.edu.
Harvard University · USNational Taiwan University · TWNational Yang Ming Chiao Tung University · TWSouthwest Hospital · CN

Funding

Photodynamic Therapy of Localized InfectionsR01AI050875 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI HAMBLIN, MICHAEL R · 2003 to 2017
$4.8M
NIAID NIH HHS R01 AI050875NIAID NIH HHS R01AI050875
6 · The paper itself

Abstract

backgroundLow-level light therapy (LLLT) is used to stimulate healing, reduce pain and inflammation, and preserve tissue from dying. LLLT has been shown to protect cells in culture from dying after various cytotoxic insults, and LLLT is known to increase the cellular ATP content. Previous studies have demonstrated that maintaining a sufficiently high ATP level is necessary for the efficient induction and execution of apoptosis steps after photodynamic therapy (PDT).

methodsWe asked whether LLLT would protect cells from cytotoxicity due to PDT, or conversely whether LLLT would enhance the efficacy of PDT mediated by mono-l-aspartyl chlorin(e6) (NPe6). Increased ATP could lead to enhanced cell uptake of NPe6 by the energy dependent process of endocytosis, and also to more efficient apoptosis. In this study, human osteosarcoma cell line MG-63 was subjected to 1.5J/cm(2) of 810nm near infrared radiation (NIR) followed by addition of 10μM NPe6 and after 2h incubation by 1.5J/cm(2) of 652nm red light for PDT.

resultsPDT combined with LLLT led to higher cell death and increased intracellular reactive oxygen species compared to PDT alone. The uptake of NPe6 was moderately increased by LLLT, and cellular ATP was increased. The mitochondrial respiratory chain inhibitor antimycin A abrogated the LLLT-induced increase in cytotoxicity.

conclusionsTaken together, these results demonstrate that LLLT potentiates NPe6-mediated PDT via increased ATP synthesis and is a potentially promising strategy that could be applied in clinical PDT.

Indexed as

Adenosine TriphosphateApoptosisCell Line, TumorCell SurvivalCombined Modality TherapyHumansLow-Level Light TherapyOsteosarcomaPhotochemotherapyPhotosensitizing AgentsPorphyrinsTreatment OutcomeAdenosine TriphosphatePhotosensitizing AgentsPorphyrinsTalaporfinAdenosine triphosphateLow level light therapyLysosomal uptakeMono-l-aspartyl chlorin(e6)PhotobiomodulationPhotodynamic therapy

Identifiers

PMID25462575
PMCPMC4361381
OpenAlexW2145593205

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.